RecruitingNCT07645820

Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares

Evaluation of a Non-Invasive Device for Early Detection of Flares in Adults and Adolescents With Atopic Dermatitis

Sponsor

Castle Biosciences Incorporated

Enrollment

450 participants

Start Date

Jun 4, 2026

Study Type

OBSERVATIONAL

Conditions

Atopic Dermatitis

Summary

This study will collect skin measurements from people with atopic dermatitis (AD) using the investigational Nevisense Go device. Participants aged 12 to 89 years with a history of AD flares will use the device at home for about 90 days. Participants will complete device measurements, electronic diary entries, and up to five in-person study visits. The study is based on the idea that changes in skin barrier function may occur before an AD flare becomes visible or symptoms begin. Information collected during the study, including device measurements, diary entries, and investigator assessments, will be used to evaluate whether these changes may help estimate the likelihood of an AD flare before visible signs or symptoms occur.

Eligibility

Min Age: 12 YearsMax Age: 89 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called Nevisense electrical impedance spectroscopy for people with atopic dermatitis. The study is currently recruiting participants at 4 locations. People eligible for this study include aged 12 Years to 89 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICENevisense electrical impedance spectroscopy

The NevisenseGo device will collect skin measurements from people with atopic dermatitis (AD) to see if it can effectively predict a flare in disease.